Previous 10 | Next 10 |
ProLectin-M , a new class of oral an t i viral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19...
Journal article published specifies the use of the MDX Viewer as an early warning sign of negative oxygen balance for use in Acute Respiratory Deficiency Syndrome (ARDS). BOSTON, MASSACHUSETTS, April 03, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developme...
Company releases new COVID-19 slide deck on website. BOSTON, MASSACHUSETTS, March 31, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale ...
Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported. BOSTON, MASSACHUSETTS, March 30, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( OTCQB:BIXT ), announced today that it intends...
The viral inhibitor is a polysaccharide designed to block galectins BOSTON, MASSACHUSETTS, March 24, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( OTCQB:BIXT ), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a ...
Live Youtube Broadcast with Expert Panelists on March 26, 2020 in MediWeb Studios BOSTON, MASSACHUSETTS, March 12, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by deliver...
Journal Article correlates different neurological pathologies with Brain Metabolic Score and examines a neurological case study BOSTON, MASSACHUSETTS, Feb. 28, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-...
Phoenix, Arizona--(Newsfile Corp. - February 12, 2020) - The Stock Day Podcast welcomed Bioxytran, Inc. (OTCQB: BIXT) ("the Company"), a developmental stage biotechnology company. CEO of the Company, David Platt, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on...
BXT-25 has the potential to treat late stage acute respiratory distress syndrome (ARDS) which is the leading cause of death in coronavirus patients. BOSTON, MASSACHUSETTS, Feb. 05, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company ...
Journal Article Evaluates Viability of Neuroprotectants as a functional Endpoint in Ischemic Stroke and Other Diseases BOSTON, MASSACHUSETTS, Dec. 05, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs ...
News, Short Squeeze, Breakout and More Instantly...
COPT Defense Properties of Beneficial Interest (CDP) is expected to report $0.64 for Q2 2024 Bank of Marin Bancorp (BMRC) is expected to report $0.19 for Q2 2024 Oak Ridge Financial Services Inc (BKOR) is expected to report for Q2 2024 D/B/A Centerspace (CSR) is expected to report $1....
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to t...
BXT-25 is expected to oxygenate the brain BOSTON, MASSACHUSETTS, June 27, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced that Bioxtran’s...